Technical Analysis for NRIX - Nurix Therapeutics, Inc.

Grade Last Price % Change Price Change
C 12.84 -1.83% -0.24
NRIX closed down 1.83 percent on Monday, March 18, 2024, on 1.73 times normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
MACD Bearish Signal Line Cross Bearish -1.83%
Volume Surge Other -1.83%
Wide Bands Range Expansion -1.83%
Calm After Storm Range Contraction -8.55%
Wide Bands Range Expansion -8.55%
Calm After Storm Range Contraction -11.33%
Wide Bands Range Expansion -11.33%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 18 hours ago
Up 3% about 18 hours ago
2x Volume Pace about 19 hours ago
1.5x Volume Pace about 20 hours ago
Down 5% about 20 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Nurix Therapeutics, Inc. Description

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications. It also provides DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a class of enzymes that could modulate proteins within the cell. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was founded in 2009 and is headquartered in San Francisco, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Treatment Of Cancer Lymphoma Enzymes Tyrosine Kinase Immune Disorders Small Molecule Therapies Gilead Sciences Bruton's Tyrosine Kinase Oncogene

Is NRIX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 16.11
52 Week Low 4.22
Average Volume 760,181
200-Day Moving Average 8.88
50-Day Moving Average 10.36
20-Day Moving Average 12.82
10-Day Moving Average 14.13
Average True Range 1.07
RSI (14) 54.13
ADX 49.43
+DI 26.50
-DI 17.94
Chandelier Exit (Long, 3 ATRs) 12.91
Chandelier Exit (Short, 3 ATRs) 12.42
Upper Bollinger Bands 16.19
Lower Bollinger Band 9.46
Percent B (%b) 0.5
BandWidth 52.48
MACD Line 1.09
MACD Signal Line 1.26
MACD Histogram -0.1678
Fundamentals Value
Market Cap 622.79 Million
Num Shares 48.5 Million
EPS -2.74
Price-to-Earnings (P/E) Ratio -4.69
Price-to-Sales 6.54
Price-to-Book 1.84
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.69
Resistance 3 (R3) 14.70 14.09 14.38
Resistance 2 (R2) 14.09 13.62 14.09 14.27
Resistance 1 (R1) 13.47 13.33 13.17 13.46 14.17
Pivot Point 12.86 12.86 12.71 12.86 12.86
Support 1 (S1) 12.24 12.39 11.94 12.23 11.51
Support 2 (S2) 11.63 12.10 11.63 11.41
Support 3 (S3) 11.01 11.63 11.30
Support 4 (S4) 11.00